HK1023571A1 - Thienotriazolodiazepine compounds and medicinal use thereof - Google Patents

Thienotriazolodiazepine compounds and medicinal use thereof

Info

Publication number
HK1023571A1
HK1023571A1 HK00102681A HK00102681A HK1023571A1 HK 1023571 A1 HK1023571 A1 HK 1023571A1 HK 00102681 A HK00102681 A HK 00102681A HK 00102681 A HK00102681 A HK 00102681A HK 1023571 A1 HK1023571 A1 HK 1023571A1
Authority
HK
Hong Kong
Prior art keywords
compound
inventive compound
useful
pharmaceutically acceptable
thienotriazolodiazepine compounds
Prior art date
Application number
HK00102681A
Other languages
English (en)
Inventor
Hiroyuki Sueoka
Hirotsugu Komatsu
Haruhito Kobayashi
Syuji Ehara
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of HK1023571A1 publication Critical patent/HK1023571A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK00102681A 1996-09-13 2000-05-03 Thienotriazolodiazepine compounds and medicinal use thereof HK1023571A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24379396 1996-09-13
PCT/JP1997/002817 WO1998011111A1 (fr) 1996-09-13 1997-08-11 Composes de thienotriazolodiazepine et leurs utilisations a des fins medicinales

Publications (1)

Publication Number Publication Date
HK1023571A1 true HK1023571A1 (en) 2000-09-15

Family

ID=17109041

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102681A HK1023571A1 (en) 1996-09-13 2000-05-03 Thienotriazolodiazepine compounds and medicinal use thereof

Country Status (15)

Country Link
EP (1) EP0989131B1 (fr)
JP (1) JP3094453B2 (fr)
KR (1) KR100338144B1 (fr)
CN (1) CN1109037C (fr)
AT (1) ATE227727T1 (fr)
AU (1) AU716490B2 (fr)
CA (1) CA2265645C (fr)
DE (1) DE69717160T2 (fr)
DK (1) DK0989131T3 (fr)
EA (1) EA001732B1 (fr)
ES (1) ES2182108T3 (fr)
HK (1) HK1023571A1 (fr)
NO (1) NO323892B1 (fr)
PT (1) PT989131E (fr)
WO (1) WO1998011111A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100838686B1 (ko) 2000-06-16 2008-06-16 미쯔비시 웰 파마 가부시키가이샤 방출 ｐＨ 범위 및/또는 속도 제어 조성물
JP5159305B2 (ja) * 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
WO2009084693A1 (fr) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation Agent antitumoral
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
JP5524343B2 (ja) 2009-11-05 2014-06-18 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤
ME02356B (fr) 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibiteur de bromodomaines vis-à-vis de la benzodiazépine
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
BR122014024883A2 (pt) * 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
GB201020015D0 (en) * 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (fr) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Inhibiteurs de bromodomaines et leurs utilisations
WO2012151512A2 (fr) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromodomaines et leurs utilisations
EP2721031B1 (fr) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (fr) 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
EP2838881B1 (fr) 2012-04-20 2018-08-08 AbbVie Inc. Dérivés d'iso-indolone
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (fr) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromo-domaine de benzo [b] isoxazoloazépines et applications associées
CN104718201A (zh) 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物
MX2014015986A (es) * 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
MX2015001880A (es) 2012-08-16 2015-05-11 Bayer Pharma AG 2,3-benzodiacepinas.
US20140107107A1 (en) * 2012-09-28 2014-04-17 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
ES2625959T3 (es) 2012-09-28 2017-07-21 Bayer Pharma Aktiengesellschaft 5-Aril-triazolo-azepinas inhibidoras de la proteína BET
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
WO2014159392A1 (fr) * 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Réactifs de liaison à des bromodomaines et leurs utilisations
WO2015013635A2 (fr) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs des facteurs de transcription et leurs utilisations
EP3027194A1 (fr) * 2013-08-01 2016-06-08 Oncoethix GmbH Préparation pharmaceutique contenant des composés de thiénotriazolodiazépine
CN103694253A (zh) * 2013-11-04 2014-04-02 湖南华腾制药有限公司 一种噻吩并***并[4,3-a][1,4]二氮杂卓类化合物的制备方法
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
JP2017504650A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
EP3099677A4 (fr) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Dérivés de diaminopyrimidine benzènesulfone et leurs utilisations
WO2015117087A1 (fr) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Utilisations des dérivés de diazépane
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
CN107074861A (zh) 2014-02-28 2017-08-18 密执安大学评议会 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
CA2955077A1 (fr) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Derives de dihydropteridinone et leurs utilisations
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
CN107257800B (zh) 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
WO2016176335A1 (fr) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Otx-015 deutéré
WO2016196065A1 (fr) 2015-05-29 2016-12-08 Genentech, Inc. Procédés et compositions pour évaluer la réponse de cancers aux inhibiteurs bet
WO2016201370A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
WO2017007612A1 (fr) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
WO2017044792A1 (fr) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acétamide thiénotriazoldiazépines et leurs utilisations
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
US11548899B2 (en) 2016-02-15 2023-01-10 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
US11192898B2 (en) 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
CA3020281A1 (fr) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Intermediaires monofonctionnels pour la degradation d'une proteine cible dependante du ligand
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
PL3442972T3 (pl) 2016-04-15 2020-07-27 Abbvie Inc. Inhibitory bromodomeny
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
JP6961684B2 (ja) 2016-09-13 2021-11-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔタンパク質分解物質としての縮合１，４−オキサゼピン
ES2857743T3 (es) 2016-09-13 2021-09-29 Univ Michigan Regents 1,4-diazepinas fusionadas como degradadores de proteína BET
WO2018064589A1 (fr) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Dégradation ciblée de protéines à l'aide d'une ubiquitine ligase e3 mutante
JP2020502148A (ja) 2016-12-16 2020-01-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ジアゼピン誘導体の製造のための方法
WO2018144789A1 (fr) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan 1,4-diazépines fusionnées utilisées en tant qu'inhibiteurs de bromodomaines bet
EP3640253A4 (fr) * 2017-05-31 2021-01-13 AYUMI Pharmaceutical Corporation Dérivé de 6h-thiéno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazépine
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN111278815B (zh) 2017-09-04 2024-03-08 C4医药公司 戊二酰亚胺
WO2019043208A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydroquinolinones
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
WO2019055444A1 (fr) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan Agents de dégradation de protéine de bromodomaine bet avec des lieurs clivables
EP3710002A4 (fr) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. Agents de dégradation et dégrons pour dégradation protéique ciblée
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
WO2019204354A1 (fr) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Composés spirocycliques
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet
TW202019946A (zh) 2018-07-04 2020-06-01 日商田邊三菱製藥股份有限公司 具有ｂｅｔ蛋白質分解誘導作用的醯胺化合物及其作為醫藥的用途
EP3936507A4 (fr) * 2019-03-07 2022-11-23 Medshine Discovery Inc. Composés ayant à la fois des effets d'inhibition de protéine de bromodomaine bet et de régulation de gène pd-l1
JP7419406B2 (ja) 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
WO2022048685A1 (fr) * 2020-09-07 2022-03-10 南京明德新药研发有限公司 Forme cristalline d'un composé d'oxime de benzotétrahydrofurane et son procédé de préparation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE870123L (en) * 1986-01-21 1987-07-21 Boehringer Ingelheim Int Thieno-1,4-diazepines
EP0368175A1 (fr) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyle)-5-(2-chlorophényle)-7,10-diméthyle-3,4-dihydro-2H,7H-cyclopenta[4,5]thiéno[3,4-f][1,2,4]triazolo[4,3-a][1,4]diazépine.
EP0387613A1 (fr) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Thiénodiazépines
YU133090A (sh) * 1989-07-12 1993-10-20 Boehringer Ingelheim Kg. Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo
WO1994006801A1 (fr) * 1990-05-23 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation comme medicament
DE4027470A1 (de) * 1990-08-30 1992-03-05 Boehringer Ingelheim Kg Neue hetrazepinoide amide
JP3239364B2 (ja) * 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
DE69230891T2 (de) * 1991-12-11 2000-10-05 Yoshitomi Pharmaceutical Arzneimittel zur Behandlung von Autoimmunerkrankungen
JP3215489B2 (ja) * 1992-04-23 2001-10-09 日本電信電話株式会社 燃料電池排熱利用システムとその制御方法
EP0661284A1 (fr) * 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
EP0692483A1 (fr) * 1993-03-30 1996-01-17 Yoshitomi Pharmaceutical Industries, Ltd. Inhibiteur d'adhesion cellulaire et compose a base de thienotriazolodiazepine
JP3633008B2 (ja) * 1993-11-15 2005-03-30 三菱ウェルファーマ株式会社 チエノトリアゾロジアゼピン化合物
JPH0879471A (ja) * 1994-09-01 1996-03-22 Konica Corp 画像形成装置

Also Published As

Publication number Publication date
EP0989131A1 (fr) 2000-03-29
AU716490B2 (en) 2000-02-24
DE69717160D1 (de) 2002-12-19
DK0989131T3 (da) 2003-03-03
CA2265645A1 (fr) 1998-03-19
JP3094453B2 (ja) 2000-10-03
NO323892B1 (no) 2007-07-16
CN1109037C (zh) 2003-05-21
ATE227727T1 (de) 2002-11-15
EP0989131B1 (fr) 2002-11-13
NO991191L (no) 1999-04-23
ES2182108T3 (es) 2003-03-01
CA2265645C (fr) 2007-01-23
KR20000036057A (ko) 2000-06-26
WO1998011111A1 (fr) 1998-03-19
NO991191D0 (no) 1999-03-11
EA001732B1 (ru) 2001-08-27
CN1237180A (zh) 1999-12-01
DE69717160T2 (de) 2003-05-08
EA199900287A1 (ru) 1999-08-26
PT989131E (pt) 2003-03-31
AU3786097A (en) 1998-04-02
KR100338144B1 (ko) 2002-05-24
EP0989131A4 (fr) 2000-03-29

Similar Documents

Publication Publication Date Title
HK1023571A1 (en) Thienotriazolodiazepine compounds and medicinal use thereof
EP0430045A3 (en) Ascorbic acid tocopheryl phosphate diesters for inhibition of maillard's reaction
SE9901573D0 (sv) New compounds
GB2220855B (en) Use of polymeric compounds in treatment
HK143095A (en) Imidazoline derivative and preparation thereof
GR3025207T3 (en) 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents
GR3019917T3 (en) Benzimidazole derivatives as antimicrobal agent against campylobacter pylon
EP1228758A4 (fr) Agents de prevention ou de traitement de maladies inflammatoires de l'intestin
IL102808A0 (en) Piperidine derivatives
SE9901572D0 (sv) New compounds
MY160429A (en) 2, 5-disubstituted 3-mercaptopentanoic acid
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
MY122570A (en) Benzamide derivatives and drugs containing the same
SE0103272D0 (sv) Chemical compounds
GB9323404D0 (en) Pharmaceuticals
HK34095A (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
SG4595G (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
DE3365781D1 (en) New 1,4-diaminocyclitol derivatives, processes for their preparation and pharmaceutical compositions containing them
ATE109003T1 (de) Therapeutisches mittel gegen pollakiurie, harndrang oder harninkontinenz, das alpha-phenyl- alpha-pyridylalkan-carbonsäurederivate enthält.
GR3030952T3 (en) Salmycins, a process for their preparation and their use as a pharmaceutical.
IT1107771B (it) Composizione farmaceutica antiartritica ed antiinfiammatoria
ES8103107A1 (es) Un procedimiento para la preparacion de un complejo de cinc.
TH13247EX (th) อนุพันธ์เททราไฮโดรฟิร์โรโล [1,2-a]ไพราชีน-4-สไพโร-3'-พิริโรลิดีน กรรมวิธีสำหรับเตรียมสารนั้นและสารผสมในทางเภสัชกรรมซึ่งมีสารนั้น

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170810